Steno Diabetes Center Copenhagen

sdc.dk

Total trials

108

Active

22

Phase 3

5

Total enrollment

15,371

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 9 of 9 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Finerenone2
Semaglutide, 1.34 mg/mL2
Dapagliflozin2
Low-Dose Glucagon1
Sotagliflozin2
Aspirin1
Semaglutide1
Novorapid1
Humalog1

Next readouts

  • 2026-11-30
  • 2026-12-31
  • 2027-05
  • 2027-05-01
  • 2029-07-01

Top conditions

  • Type 1 Diabetes22
  • Diabetes Mellitus, Type 114
  • Type 2 Diabetes11
  • Diabetes Mellitus, Type 210
  • Hypoglycemia10
  • Non-Alcoholic Fatty Liver Disease4
  • Nephropathy4
  • Diabetes Mellitus4

Frequently asked questions about Steno Diabetes Center Copenhagen

How many clinical trials does Steno Diabetes Center Copenhagen have on ClinicalTrials.gov?
Steno Diabetes Center Copenhagen is listed as the lead sponsor on 108 clinical trials in ClinicalTrials.gov, 22 of which are currently active (recruiting, enrolling, or ongoing).
How many of Steno Diabetes Center Copenhagen's trials are in Phase 3?
5 of Steno Diabetes Center Copenhagen's trials are in Phase 3, spread across 9 active drug programs.
What therapeutic areas does Steno Diabetes Center Copenhagen focus on?
Steno Diabetes Center Copenhagen's most-studied conditions on ClinicalTrials.gov are Type 1 Diabetes, Diabetes Mellitus, Type 1, Type 2 Diabetes, Diabetes Mellitus, Type 2, Hypoglycemia.
When are Steno Diabetes Center Copenhagen's next clinical trial readouts?
Steno Diabetes Center Copenhagen has 5 upcoming primary-completion readouts tracked here; the soonest is “Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study”, expected around 2026-11-30.